WO2022092326A1 - 眼組織線維化の阻害に使用するためのgdf15調節物質 - Google Patents
眼組織線維化の阻害に使用するためのgdf15調節物質 Download PDFInfo
- Publication number
- WO2022092326A1 WO2022092326A1 PCT/JP2021/040902 JP2021040902W WO2022092326A1 WO 2022092326 A1 WO2022092326 A1 WO 2022092326A1 JP 2021040902 W JP2021040902 W JP 2021040902W WO 2022092326 A1 WO2022092326 A1 WO 2022092326A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- sequence
- cdr
- gdf15
- antibody
- Prior art date
Links
- 206010016654 Fibrosis Diseases 0.000 title claims abstract description 66
- 230000004761 fibrosis Effects 0.000 title claims abstract description 65
- 102000000597 Growth Differentiation Factor 15 Human genes 0.000 title abstract description 157
- 230000005764 inhibitory process Effects 0.000 title description 3
- 101150085449 Gdf15 gene Proteins 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 96
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 39
- 208000035475 disorder Diseases 0.000 claims abstract description 27
- 239000000126 substance Substances 0.000 claims abstract description 15
- 230000009471 action Effects 0.000 claims abstract description 14
- 238000011282 treatment Methods 0.000 claims description 45
- 230000000694 effects Effects 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 26
- 208000002780 macular degeneration Diseases 0.000 claims description 26
- 229940079593 drug Drugs 0.000 claims description 23
- 239000003112 inhibitor Substances 0.000 claims description 21
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 claims description 20
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 14
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 10
- 201000011190 diabetic macular edema Diseases 0.000 claims description 9
- 230000002207 retinal effect Effects 0.000 claims description 9
- 230000033115 angiogenesis Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 208000026726 vitreous disease Diseases 0.000 claims description 8
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 7
- 208000037111 Retinal Hemorrhage Diseases 0.000 claims description 7
- 206010038848 Retinal detachment Diseases 0.000 claims description 7
- 208000017442 Retinal disease Diseases 0.000 claims description 7
- 206010038923 Retinopathy Diseases 0.000 claims description 7
- 230000002062 proliferating effect Effects 0.000 claims description 7
- 230000004264 retinal detachment Effects 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 201000009310 astigmatism Diseases 0.000 claims description 6
- 239000005557 antagonist Substances 0.000 claims description 5
- 206010029113 Neovascularisation Diseases 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 3
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 201000007737 Retinal degeneration Diseases 0.000 claims 1
- 208000038015 macular disease Diseases 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 230000004258 retinal degeneration Effects 0.000 claims 1
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 abstract description 156
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 210
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 210
- 150000001413 amino acids Chemical group 0.000 description 82
- 210000004027 cell Anatomy 0.000 description 68
- 239000000203 mixture Substances 0.000 description 54
- 230000014509 gene expression Effects 0.000 description 46
- 210000001519 tissue Anatomy 0.000 description 46
- 108090000623 proteins and genes Proteins 0.000 description 39
- 108020004414 DNA Proteins 0.000 description 35
- 102000005962 receptors Human genes 0.000 description 29
- 108020003175 receptors Proteins 0.000 description 29
- 241000700605 Viruses Species 0.000 description 26
- 239000013598 vector Substances 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 18
- 239000013603 viral vector Substances 0.000 description 15
- 239000013604 expression vector Substances 0.000 description 14
- 210000001508 eye Anatomy 0.000 description 14
- 102000039446 nucleic acids Human genes 0.000 description 14
- 108020004707 nucleic acids Proteins 0.000 description 14
- 150000007523 nucleic acids Chemical class 0.000 description 14
- 231100000241 scar Toxicity 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 230000003176 fibrotic effect Effects 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 108020004459 Small interfering RNA Proteins 0.000 description 11
- -1 bandetanib Chemical compound 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 241000701161 unidentified adenovirus Species 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 241000282412 Homo Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 210000000130 stem cell Anatomy 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- 238000005070 sampling Methods 0.000 description 8
- 102000016359 Fibronectins Human genes 0.000 description 7
- 108010067306 Fibronectins Proteins 0.000 description 7
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 102000046181 human GDF15 Human genes 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 210000001525 retina Anatomy 0.000 description 7
- 230000036573 scar formation Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 6
- 238000012744 immunostaining Methods 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000003889 eye drop Substances 0.000 description 5
- 238000001361 intraarterial administration Methods 0.000 description 5
- 239000002105 nanoparticle Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102100040304 GDNF family receptor alpha-like Human genes 0.000 description 4
- 102000005720 Glutathione transferase Human genes 0.000 description 4
- 108010070675 Glutathione transferase Proteins 0.000 description 4
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 4
- 101001038371 Homo sapiens GDNF family receptor alpha-like Proteins 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 241000713666 Lentivirus Species 0.000 description 4
- 108091061960 Naked DNA Proteins 0.000 description 4
- 108010052160 Site-specific recombinase Proteins 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 239000004037 angiogenesis inhibitor Substances 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 210000005252 bulbus oculi Anatomy 0.000 description 4
- 229940012356 eye drops Drugs 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002452 interceptive effect Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 description 3
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 description 3
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 3
- 206010025421 Macule Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 108010091086 Recombinases Proteins 0.000 description 3
- 102000018120 Recombinases Human genes 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 102100023345 Tyrosine-protein kinase ITK/TSK Human genes 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 230000003444 anaesthetic effect Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000006059 cover glass Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229960003299 ketamine Drugs 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 229950002216 linifanib Drugs 0.000 description 3
- MPVGZUGXCQEXTM-UHFFFAOYSA-N linifanib Chemical compound CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000002997 ophthalmic solution Substances 0.000 description 3
- 229940054534 ophthalmic solution Drugs 0.000 description 3
- 210000003733 optic disk Anatomy 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000000790 retinal pigment Substances 0.000 description 3
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 3
- 229960001600 xylazine Drugs 0.000 description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 241000713704 Bovine immunodeficiency virus Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 2
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 description 2
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 description 2
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 description 2
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 description 2
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 description 2
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 2
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 2
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 101100392289 Mus musculus Gdf15 gene Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 101100392290 Rattus norvegicus Gdf15 gene Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 206010047531 Visual acuity reduced Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 108010081667 aflibercept Proteins 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000002617 apheresis Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 229960003005 axitinib Drugs 0.000 description 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 2
- 239000008228 bacteriostatic water for injection Substances 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 230000008236 biological pathway Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229960001292 cabozantinib Drugs 0.000 description 2
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 2
- 239000012830 cancer therapeutic Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 210000003161 choroid Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 102000054751 human RUNX1T1 Human genes 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229960000639 pazopanib Drugs 0.000 description 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229960003876 ranibizumab Drugs 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 229960004836 regorafenib Drugs 0.000 description 2
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960001796 sunitinib Drugs 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000012929 tonicity agent Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 101150094949 APRT gene Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
- 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000713730 Equine infectious anemia virus Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102100035233 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000016621 Hearing disease Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 206010020675 Hypermetropia Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108091008551 RET receptors Proteins 0.000 description 1
- 102000004879 Racemases and epimerases Human genes 0.000 description 1
- 108090001066 Racemases and epimerases Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 241000713675 Spumavirus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 108091005735 TGF-beta receptors Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108010010574 Tn3 resolvase Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 206010047555 Visual field defect Diseases 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 210000000411 amacrine cell Anatomy 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229940051306 eylea Drugs 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 210000002287 horizontal cell Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000004305 hyperopia Effects 0.000 description 1
- 201000006318 hyperopia Diseases 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940076783 lucentis Drugs 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229940045847 receptor mimetic Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Definitions
- the main object of the present invention is to provide a new inhibitor of ocular tissue fibrosis.
- the GDF15 regulator reduces or inhibits GDF15 activity.
- the GDF15 regulator is an anti-GDF15 antibody, eg, a humanized or human antibody.
- the anti-GDF15 antibody is: (I) of the CDR H1 sequence of SEQ ID NO: 1, the CD H2 sequence of SEQ ID NO: 7, the CDR H3 sequence of SEQ ID NO: 13, and the CDR L1 sequence of SEQ ID NO: 16, the CDR L2 sequence of SEQ ID NO: 18, and SEQ ID NO: 22.
- the invention provides a GDF15 regulator for use in treating ocular fibrosis disorders in subjects in need of treatment for ocular fibrosis disorders.
- the disorder is age-related macular degeneration (eg, wet age-related macular degeneration), refractory retinal vitreous disease (eg, proliferative vitreous retinopathy or diabetic retinopathy), diabetic macular degeneration (DME). , Retinal hemorrhage, retinal detachment, old eye, choroidal angiogenesis, subfoveal or parafoveal neovascularization, macular degeneration, and crystalline macular degeneration.
- age-related macular degeneration eg, wet age-related macular degeneration
- refractory retinal vitreous disease eg, proliferative vitreous retinopathy or diabetic retinopathy
- DME diabetic macular degeneration
- Retinal hemorrhage retinal detachment, old eye, choroidal
- the present invention provides an ocular tissue fibrosis inhibitor containing a substance that inhibits the action of GDF15 (Growth Differentiation Factor 15) as an active ingredient.
- GDF15 Crowth Differentiation Factor 15
- the ocular tissue may be retinal pigment epithelial cells.
- a to D show the result of Example 1.
- a to D show the results of Example 2.
- a to B show the results of Example 3.
- a to F show the results of Example 4.
- a to C show the results of Example 5.
- a to C show the results of Example 6.
- the ocular tissue fibrosis inhibitor according to the present invention is characterized in that it contains a substance that inhibits the action of GDF15 (Growth Difference Factor 15) as an active ingredient.
- GDF15 Crowth Difference Factor 15
- Epithelial-mesenchymal transition is the process by which epithelial cells transform into mesenchymal-like cells. The process transforms epithelial cells into myofibroblast-like cells, leading to fibrous scar formation. Since it has been known that the expression of EMT-related factors is regulated by growth factors and cytokines, the inventors of the present application thought that elucidation of EMT-related factors would lead to elucidation of pathological conditions.
- GDF15 As a result of diligent experimental studies, the inventors of the present application focused on the above-mentioned GDF15, and as shown in Examples described later, the expression of GDF15 increased under the pathological condition of fibrotic scar, so that GDF15 was interepithelial. By inducing leaf conversion, it was found to be involved in the progression of fibrotic pathology. Therefore, it was revealed that a substance that inhibits the action of GDF15 can suppress fibrotic scar formation in the eye.
- the "GDF15 regulator” or “substance that inhibits the action of GDF15” refers to the expression level, biological activity and biological function of GDF15 and / or the biological pathway of GDF15.
- the substance that inhibits the action of GDF15 is not particularly limited, and for example, an antagonist of GDF15, an anti-GDF15 antibody, an antagonist of GDF15-specific receptor, an anti-GDF15-specific receptor antibody, and inhibition of downstream signals of GDF15-specific receptor.
- GDF15 expression inhibitors GDF15-specific receptor expression inhibitors
- soluble GDF15 mimetics or analogs that prevent GDF15 from binding to its cognate-binding partner, GDF15 to bind to its cognate-binding partner.
- a soluble GDF15 receptor mimetic or analog that blocks, a small molecule inhibitor of GDF15 or GDF15 receptor, an interfering nucleic acid (eg, an interfering RNA or antisense nucleic acid that interferes with the expression of an endogenous GDF15 or cognate receptor (eg, anti).
- Sense DNA or RNA Sense DNA or RNA
- these substances may be used alone or in combination of two or more thereof. Further, these substances can be obtained by purification by a known method, or are commercially available products. It can also be obtained as.
- An exemplary anti-GDF15 antibody useful in the methods and compositions of the invention is, for example, one of the four sets of CDR L1 , CDR L2 , and CDR L3 region sequences defined in Table 2 below. It may include a light chain variable region containing.
- an exemplary anti-GDF15 antibody is (I) CDR H1 containing the amino acid sequence of SEQ ID NO: 1, CDR H2 containing the amino acid sequence of SEQ ID NO: 7, CDR H3 containing the amino acid sequence of SEQ ID NO: 13, CDR L1 containing the amino acid sequence of SEQ ID NO: 16, SEQ ID NO: 18 CDR L2 containing the amino acid sequence of, and CDR L3 containing the amino acid sequence of SEQ ID NO: 22.
- the anti-GDF15 antibody comprises CDR H1 comprising the amino acid sequence of SEQ ID NO: 1, CDR H2 comprising the amino acid sequence of SEQ ID NO: 7, CDR H3 comprising the amino acid sequence of SEQ ID NO: 13, and the amino acid sequence of SEQ ID NO: 16.
- CDR L1 including, CDR L2 containing the amino acid sequence of SEQ ID NO: 18, and CDR L3 containing the amino acid sequence of SEQ ID NO: 22.
- anti-GDF-15 antibodies useful in the practice of the present invention are described in US Patent Application Publication No. 2014/01/93427 (this disclosure is incorporated herein by reference in its entirety). Includes 01G06, 03G05, 04F08, 06C11, 08G01, 14F11, 17B11, and their human or humanized forms.
- Exemplary anti-GDF15 antibodies useful in the methods and compositions of the invention may include, for example, a light chain variable region comprising the sequences of the CDR L1 , CDR L2 , and CDR L3 regions defined in Table 5 below.
- Exemplary anti-GDF15 antibodies useful in the methods and compositions of the invention are defined, for example, in (i) the sequences of the CDR H1 , CDR H2 , and CDR H3 regions set forth in Table 8 and (ii) Table 9. It may include sequences of CDR L1 , CDR L2 , and CDR L3 regions.
- exemplary anti-GDF15 antibodies include CDR H1 comprising the amino acid sequence of SEQ ID NO: 111, CDR H2 comprising the amino acid sequence of SEQ ID NO: 112, CDR H3 comprising the amino acid sequence of SEQ ID NO: 113, and the amino acid sequence of SEQ ID NO: 114. It may include CDR L1 including, CDR L2 containing the amino acid sequence of SEQ ID NO: 115, and CDR L3 containing the amino acid sequence of SEQ ID NO: 116.
- An exemplary anti-GDF15 receptor antibody is an anti-GFRAL antibody.
- GFLAL is a GDF15 receptor (Mullican et al. (2017) Nature Medicine, 23: 11501-157, Emmerson et al. (2017) Nature Medicine, 23: 1215-1219, Hu et al. (2017) Nature, 550: 255-259, and Yang et al. (2017) Nature Medicine, 23: 1158-1166, these disclosures are incorporated herein by reference in their entirety).
- An exemplary anti-GFRAL antibody useful in the methods and compositions of the invention is, for example, one of the six sets of CDR H1 , CDR H2 , and CDR H3 region sequences defined in Table 12 below. It may include a heavy chain variable region containing.
- An exemplary anti-GFRAL antibody useful in the methods and compositions of the invention may include, for example, any one of the two sets of heavy chain variable region and light chain variable region sequences defined in Table 14. ..
- the substance that inhibits the action of GDF15 is preferably an anti-GDF15 antibody containing the above-mentioned GDF15-binding fragment or the like, or an antagonist of a GDF-specific receptor, and is an anti-GDF15 antibody. Is more preferable.
- the antibody may be a neutralizing antibody that reduces GDF15 activity.
- the antibody is measured for GDF15 activity in an in vivo assay (see, eg, Johanne et al., 2007, Nature Medicine 13: 1333-1340) in the same assay, in the absence of the antibody.
- the activity may be reduced by at least 10%, preferably 20%, 30% or 40%, more preferably at least about 50%, 60%, 80% or 90% of GDF15 as compared to GDF15 activity.
- the antibody may selectively and / or significantly reduce or inhibit the binding of GDF15 to its endogenous receptor.
- the term "significantly reduces or inhibits binding" between GDF15 and its receptor means that the antibody inhibits GDF15 binding and its efficacy or percent inhibition is in the absence of said antibody.
- the binding is performed, for example, by Tsai et al. , 2013, PLOS One, 8: e55174, can be measured using the direct method or sandwich method of enzyme-linked immunosorbent assay (ELISA).
- the engineered gene When expressed in a host eukaryotic cell, eg, a CHO cell, it is first inserted into an expression vector containing a suitable eukaryotic promoter, secretory signal, poly A sequence, and stop codon.
- the vector or gene construct may include enhancers and introns.
- the expression vector optionally comprises a sequence encoding all or part of the constant region, allowing all or part of the heavy or light chain to be expressed.
- the gene construct can be introduced into the host eukaryotic cell using prior art.
- each humanized antibody has the same or substantially the same affinity for the antigen as the non-humanized mouse antibody from which it is derived.
- One method of humanization is to produce a chimeric protein in which the mouse immunoglobulin constant region is replaced with the human immunoglobulin constant region.
- Morrison et al. 1984, Proc. Nat. Acad. Sci. 81: 6851-6855, Neuberger et al. , 1984, Nature 312: 604-608, US Pat. Nos. 6,893,625 (Robinson), 5,500,362 (Robinson), and 4,816,567 (Cabilly).
- compositions and methods disclosed herein can be used to treat various forms of eye disorders in a subject.
- the present invention provides methods for reducing ocular fibrosis and / or treating ocular fibrosis disorders in a subject.
- the method is to administer an effective amount of a GDF15 regulator, eg, an anti-GDF15 antibody, to the subject alone or in combination with another therapeutic agent to reduce or treat such disorders in the subject. include.
- treat refers to the treatment of a disease in a subject, eg, in a human. This includes (a) inhibiting the disease, i.e. stopping its onset, and (b) alleviating the disease, i.e., resulting in regression of the disease state.
- subject and “patient” refer to an organism to be treated by the methods and compositions described herein. Such organisms preferably include, but are not limited to, mammals (eg, mice, monkeys, horses, cows, pigs, dogs, cats, etc.) and more preferably humans.
- the GDF15 regulator is administered in combination with an anti-angiogenic agent.
- the antiangiogenic agents are afribercept, anti-VEGF antibodies (eg, bevacizumab and ranibizumab), sunitinib, pazopanib, sorafenib, regorafenib, bandetanib, cabozantinib, axitinib, tubozantinib, linifanib, tibozanib, linifanib.
- compositions containing GDF15 regulators can be formulated into dosage forms or units of dosage using standard pharmaceutical techniques. However, the pharmaceutical composition should be formulated to fit its intended route of administration.
- the ocular tissue fibrosis inhibitor according to the present invention can be formulated by adding a pharmaceutically acceptable additive as necessary and using a technique widely used as a single preparation or a combination preparation.
- compositions described herein can be administered to a subject by any route, including intravenously (eg, by infusion pump), intraperitoneal, intraocular, intraarterial, intrapulmonary, oral. , Inhalation, Intravesical, Intramuscular, Intratracheal, Subcutaneous, Intraocular, Intrathecal, Percutaneous, Transthoracic, Intraarterial, Local, Inhalation (eg, as a spray), Mucosa (nasal mucosa, etc.), Subcutaneous, transdermal, gastrointestinal, intra-arterial, intratubal, intraventricular, rectal (ie, by suppository), vagina (ie, by pessary), intracranial, intraurethral, intrahepatic, and intratumoral.
- intravenously eg, by infusion pump
- intraperitoneal intraocular, intraarterial, intrapulmonary, oral.
- Inhalation Intravesical, Intramuscular, Intratracheal
- Injections are, for example, bacteriostatic water for injection, physiological saline, oil, diluents such as polyethylene glycol, glycerin, propylene glycol; antibacterial agents such as benzyl alcohol and methylparaben; antioxidants such as ascorbic acid and sodium chloride; A chelating agent such as EDTA; a buffer solution such as acetate, citrate, and phosphoric acid; an isotonic agent such as sodium chloride and dextrose can be appropriately selected and used for formulation.
- physiological saline such as polyethylene glycol, glycerin, propylene glycol
- antibacterial agents such as benzyl alcohol and methylparaben
- antioxidants such as ascorbic acid and sodium chloride
- a chelating agent such as EDTA
- a buffer solution such as acetate, citrate, and phosphoric acid
- an isotonic agent such as sodium chloride and dextrose can be appropriately selected and used for formulation.
- Human doses can be optimized, for example, in conventional Phase I dose escalation studies designed to be performed at 0.5 mg / kg to 20 mg / kg.
- the frequency of administration may vary depending on factors such as route of administration, dose, serum half-life of the composition (eg, antibody), and the disease to be treated.
- the exemplary dosing frequency is once daily, once weekly and once every two weeks.
- the amount of GDF15 regulator administered to the subject is, for example, from about 10 ⁇ g to about 50 ⁇ g, from about 50 ⁇ g to about 100 ⁇ g, from about 100 ⁇ g to about 200 ⁇ g, from about 200 ⁇ g to about 300 ⁇ g, from about 300 ⁇ g to.
- the GDF15 regulator is about 0.025 mg to about 4 mg, about 0.035 mg to about 2 mg, about 0.05 mg to about 2 mg, about 0.1 mg to about 2 mg of the administrable GDF15 regulator. It is administered at a dose of about 0.2 mg to about 1 mg, or about 0.2 mg to about 0.8 mg. In one embodiment, 0.5 mg of GDF15 regulator is administered topically. In other specific embodiments, about 0.05 mg to about 2 mg, about 0.2 mg to about 2 mg, about 0.05 mg to about 1.5 mg, about 0.15 mg to about 1.5 mg, about 0.4 mg to about. 1 mg, or about 0.5 mg to about 0.8 mg of GDF15 regulator, is administered topically.
- the GDF15 regulator composition may be administered once daily, or the total daily dose may be administered in divided doses of twice, three or four times daily.
- the composition is also less frequently than once a day, eg, 6 times a week, 5 times a week, 4 times a week, 3 times a week, 2 times a week, once a week, once every two weeks, once every three weeks. It can be administered once a month, once every two months, once every three months, or once every six months.
- the composition may also release the composition to be used gradually over a period of time, and the composition may be administered at a low frequency such as once a month, once every 2 to 6 months, once a year, or even a single dose. It can be administered in a sustained release formulation, such as an implantable tablet.
- Sustained release devices eg, pellets, nanoparticles, microparticles, nanoparticles, microspheres, etc.
- Sustained release devices can be administered by injection or surgically implanted in various parts of the
- administration of the GDF15 regulator is adjusted such that the dose reduces or prevents adverse effects, but is still sufficient to completely or partially inhibit the activity of GDF15. ..
- the activity of GDF15 can be regulated within the target cell using antisense nucleic acid or small molecule interfering nucleic acid.
- Modulation is an expression construct known in the art for expressing a nucleic acid encoding an anti-GDF15 siRNA or antisense molecule, such as a bare DNA construct, a construct using a DNA vector, and / or a viral vector and / or. It can be achieved using constructs with viruses.
- DNA constructs and the therapeutic use of such constructs are well known to those of skill in the art (eg, Chiarella et al., 2008, Recent Patents Anti-Infect.Drug Disc., 3: 93-101, Gray et al. , 2008, Expert Opin. Biol. Ther., 8: 911-922, Melman et al., 2008, Hum. Gene Ther., 17: 1165-1176).
- Naked DNA constructs typically include one or more therapeutic nucleic acids (eg, GDF15 regulators) and promoter sequences.
- the bare DNA construct can be a DNA vector commonly referred to as pDNA. Naked DNA is typically not integrated into chromosomal DNA. In general, bare DNA constructs do not require or combine with the presence of lipids, polymers, or viral proteins. Such constructs also include one or more of the non-therapeutic ingredients described herein.
- DNA vectors are known in the art and they are typically circular double-stranded DNA molecules. DNA vectors typically range in size from 3 to 5 kilobase pairs (eg, include inserted therapeutic nucleic acids). Like bare DNA, DNA vectors can be used to deliver and express one or more therapeutic proteins to target cells. DNA vectors are not integrated into chromosomal DNA.
- a DNA vector contains at least one promoter sequence that allows replication within the target cell. Incorporation of the DNA vector can be facilitated, for example, by combining the DNA vector with a cationic lipid and forming a DNA complex.
- a viral vector is a double-stranded circular DNA molecule derived from a virus. Viral vectors are typically larger in size than bare DNA and DNA vector constructs and have greater ability to introduce foreign (ie, not encoded by virus) genes. Like naked DNA and DNA vectors, viral vectors can be used to deliver and express one or more therapeutic nucleic acids to target cells. Unlike naked DNA and DNA vectors, certain viral vectors stably integrate themselves into chromosomal DNA.
- retroviral vectors adenovirus-derived vectors, and / or adeno-related viral vectors as recombinant gene delivery systems for in vivo exogenous gene transfer, especially to humans.
- Protocols for producing recombinant retroviruses and infecting cells in vitro or in vivo with such viruses are described in Current Protocols in Molecular Biologic, Ausubel, F. et al. M. et al. (Eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14, and other standard experimental manuals.
- the adenovirus can be used according to the methods described herein.
- the adenovirus genome can be engineered to encode and express the gene product of interest, but be inactive with respect to its replication capacity during its normal oncolytic life cycle.
- Suitable adenovirus vectors derived from the adenovirus strain Ad5 type dl324 or other strains of adenovirus (eg, Ad2, Ad3, Ad7, etc.) are known to those of skill in the art.
- Recombinant adenoviruses can be advantageous in certain situations where non-dividing cells cannot be infected and can be used to infect a wide variety of cell types, including epithelial cells.
- the virus particles are relatively stable, easy to purify and concentrate, and can be modified to affect the range of infectivity as described above.
- the introduced adenoviral DNA (and the foreign DNA contained therein) does not integrate into the genome of the host cell but stays in the episome, so that the introduced DNA is integrated into the host genome (eg, retroviral DNA).
- the host genome eg, retroviral DNA
- Potential problems resulting from insertion mutations in the insitu are avoided.
- the capacity of foreign DNA in the adenovirus genome is large (up to 8 kilobases) compared to other gene delivery vectors.
- Adeno-associated virus is a naturally occurring deficient virus that requires another virus, such as adenovirus or herpesvirus, as a helper virus for efficient replication and productive life cycle. This virus is also one of the few viruses that can integrate its DNA into non-dividing cells and frequently exhibits stable integration.
- the transfected cells are embryonic stem cells, bone marrow stem cells, umbilical cord stem cells, placenta stem cells, mesenchymal stem cells, neural stem cells, liver stem cells, pancreatic stem cells, heart stem cells, kidney stem cells, or hematopoietic stem cells. be.
- a host cell transduced with a viral vector according to the invention, expressing one or more polypeptides is administered to a subject to treat and / or prevent a hearing disorder, disorder, or condition. Will be done.
- Other methods associated with the use of viral vectors include, for example, Kay, 1997, Chest, 111 (6 Supp.): 138S-142S, Ferry et al. , 1998, Hum. Gene Ther. , 9: 1975-81, Shiratory et al. , 1999, Liver, 19: 265-74, Oka et al. , 2000, Curr. Opin. Lipidol. , 11: 179-86, Thule et al.
- conditional expression of the polynucleotide of interest is provided.
- expression is controlled by subjecting cells, tissues, organisms, etc. to a treatment or condition that causes expression of the polynucleotide or causes an increase or decrease in the expression of the polynucleotide encoded by the polynucleotide of interest.
- inducible promoters / systems include steroid-inducible promoters (which can be induced by treatment with the corresponding hormone), metallothionine promoters (various), such as promoters of genes encoding glucocorticoids or estrogen receptors.
- MX-1 promoter inducible by interferon
- GeneSwitch mifepriston control system
- cuminate inducible Examples include, but are not limited to, a gene switch (WO2002 / 088346), a tetracycline-dependent control system, and the like.
- 12, 15, 20, 30, 50, etc. include excised or integrated proteins, enzymes, cofactors or related proteins involved in recombinant reactions, which are wild proteins (Landy, 1993, It can be a Currency Opinion in Biotechnology, 3: 699-707), or a variant, derivative (eg, a fusion protein containing a recombinant protein sequence or fragment thereof), a fragment, and a variant thereof.
- Examples of exemplary recombinases suitable for use in certain embodiments of the invention include Cre, Int, IHF, Xis, Flp, Fis, Hin, Gin, OC31, Cin, Tn3 Resolvase, TndX, XerC, XerD, Examples include, but are not limited to, TnpX, Hjc, Gin, SpCCEI, and ParA.
- the vector comprises a selectable gene, also referred to as a selectable marker.
- selectable genes include (a) proteins that confer resistance to antibiotics or other toxins such as ampicillin, neomycin, hyglomycin, methotrexate, ZEOCIN, blastsidedin, or tetracycline, (b) nutritional deficiencies.
- DNA delivery is described, for example, in US Pat. Nos. 5,543,158, 5,641,515, and 5,399,363, respectively, specifically herein by reference in its entirety. It can also be done parenterally, intravenously, intramuscularly, or intraperitoneally, as described in (Incorporated in the Book).
- a solution of the active compound as a free base or a pharmacologically acceptable salt can be prepared in water which is suitably mixed with a surfactant such as hydroxypropyl cellulose.
- Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof, and oils. Under normal storage and use conditions, these preparations contain preservatives to prevent the growth of microorganisms.
- Exemplary formulations for DNA exovivo delivery also include the use of various transfection agents known in the art, such as calcium phosphate, electroporation, heat shock and various liposomal formulations (ie, lipid-mediated transfections). obtain.
- specific embodiments of the present invention include other formulations, such as those well known in the pharmaceutical field, and, for example, Remington: The Science and Practice of Pharmacy, 20th Edition. Baltimore, MD: Lippincott Williams & Wilkins, 2000, etc. may be included.
- GDF15 activity is inhibited by contacting the body fluid with a composition comprising a GDF15 regulator with an exovibo under conditions where the GDF15 regulator can reduce or inhibit GDF15 activity.
- suitable body fluids include those that can be returned to an individual, such as blood, plasma, or lymph.
- Apheresis adsorption apheresis is described by Nilsson et al. , 1988, Blood, 58 (1): 38-44, Christie et al. , 1993, Transfusion, 33: 234-242, Richter et al. , 1997, ASAIO J.M. , 43 (1): 53-59, Suzuki et al. , 1994, Autoimmunity, 19: 105-112, US Pat. No.
- the present invention is a method of treating one or more of the disorders described herein in a subject, such condition under conditions where the GDF15 regulator can reduce or inhibit GDF15 activity in the subject's blood.
- Includes methods comprising treating a subject's blood extracorporeally (ie, outside the body or exobibo) with a composition comprising.
- the ocular tissue fibrosis inhibitor according to the present invention is also useful as a dietary supplement (food and drink) orally or via the intestinal tract.
- a dietary supplement food and drink
- various conventionally known forms and types can be adopted.
- the ocular tissue fibrosis inhibitor according to the present invention can also be used as a food additive.
- When taken as a dietary supplement about 0.1 mg / kg to 100 mg / kg per day is taken once or in several divided doses. Further, if necessary, an amount outside the above range can be used.
- GDF15 is involved in fibrotic scar formation associated with choroidal angiogenesis.
- a 7 1 mixed anesthetic solution of ketamine and xylazine diluted 10-fold with physiological saline (1 mL / kg) was administered intramuscularly to the thigh muscles of mice. Then, 0.1% of Hyalein (registered trademark) ophthalmic solution was instilled so that the eyeball would not dry out. While pointing the cover glass to the right eye, look into the fundus of the eye and use a laser photocoagulator (MC500) to irradiate the circumference of the optic nerve head with 6 lasers at regular intervals (wavelength: 647 nm, spot size: 50 ⁇ m, irradiation). Time: 100 msec, laser output: 120 mW).
- MC500 laser photocoagulator
- RAW264.7 which is a macrophage cell
- RAW264.7 which is a macrophage cell
- the medium was exchanged under 1% FBS conditions, and the cells were cultured for 1 hour.
- an inflammation-inducing agent Lipopolysaccharide (LPS)
- LPS Lipopolysaccharide
- FIGS. 2A to 2B show the localization of GDF15 and macrophage markers.
- GDF15 co-localized with Iba-1 (macrophage marker) in the CNV lesion.
- 2C, D and E show the expression of GDF15 in activated macrophage cells.
- LPS treatment increased the production of activated GDF15 in macrophage cells.
- the source of GDF15 whose expression is increased under fibrotic pathology is macrophages.
- FIGS. 3A to 3B show the effect of GDF15 treatment on the cell morphology of retinal pigment epithelial cells.
- the addition of GDF15 induced an EMT-like morphological change in which the cell morphology became spindle-shaped.
- GDF15 promotes fibrosis-like transformation of retinal pigment epithelial cells.
- ARPE-19 a human retinal pigment epithelial cell line
- a human retinal pigment epithelial cell line was seeded in 24 and 96-well plates at 2.5 ⁇ 10 4 cells / well and 5.0 ⁇ 10 3 cells / well, respectively, to be 90% confluent. It was cultured for 4 days until it became. When 90% confluent was reached, the medium was exchanged under 1% FBS conditions and cultured for 24 hours. After the medium was exchanged again, human recombinant GDF15 (AVISCERA BIOSCIENCE) and human recombinant TGF ⁇ 1 (R & D systems) known as a fibrosis promoting factor were added. The drug was added every 2 days, and sampling was performed 144 hours after the addition, and changes in protein expression of fibronectin (fibrosis marker) were examined by Western blotting and immunostaining.
- FIGS. 4A to 4F show changes in fibronectin protein expression due to the addition of GDF15.
- the addition of GDF15 increased the expression of fibronectin, a fibrosis marker.
- GDF15 acts to promote fibrosis on retinal pigment epithelial cells.
- Example 5 In Experimental Example 5, the action of a neutralizing antibody targeting GDF15 was investigated.
- ARPE-19 a human retinal pigment epithelial cell line
- a human retinal pigment epithelial cell line was seeded in 96-well plates at 5.0 ⁇ 10 3 cells / well and cultured for 4 days until 90% confluent.
- the medium was exchanged under 1% FBS conditions and cultured for 24 hours.
- Human GDF-15 Antibody Product No .: AF957, manufactured by R & D, Source: Polyclonal Goat IgG
- human recombinant GDF15 AVISCERA BIOSCIE
- FIGS. 5A to 5B show the effect of the anti-GDF15 antibody on retinal pigment epithelial cell fibrosis.
- the addition of the anti-GDF15 antibody suppressed the increase in GDF15-induced fibronectin expression in a concentration-dependent manner.
- anti-GDF15 antibody is useful for suppressing fibrosis in retinal pigment epithelial cells.
- FIGS. 6A to 6C show changes in the expression of downstream signals due to the addition of GDF15. Phosphorylation of the downstream signals Realranged daring transfection (RET), AKT and GSK3 ⁇ of the GFRAL receptor, which has a high affinity for GDF15, was enhanced.
- RET Realranged daring transfection
- AKT AKT
- GSK3 ⁇ of the GFRAL receptor which has a high affinity for GDF15
- the GFRAL receptor is a receptor having a high affinity for GDF15 as described above, the above signal does not move with TGF ⁇ and is peculiar to GDF15.
- the present invention is useful for the radical treatment of ocular tissue fibrosis, contributes to the suppression of visual acuity deterioration in patients with predicted fibrotic scar formation, and also in the rehabilitation of the patients and the reduction of medical expenses. It is thought that it will be connected.
Abstract
Description
本願は、日本国特許庁にて2020年10月30日に出願された日本国特許出願第2020−182538号に対する優先権を主張するものであり、該出願は、参照によりその全体が本明細書に援用される。
(i)配列番号1のCDRH1配列、配列番号7のCDH2配列、及び配列番号13のCDRH3配列、ならびに配列番号16のCDRL1配列、配列番号18のCDRL2配列、及び配列番号22のCDRL3配列を含む抗体、
(ii)配列番号1のCDRH1配列、配列番号9のCDH2配列、及び配列番号13のCDRH3配列、ならびに配列番号16のCDRL1配列、配列番号18の配列、及び配列番号22のCDRL3配列を含む抗体、
(iii)配列番号1のCDRH1配列、配列番号4のCDH2配列、及び配列番号13のCDRH3配列、ならびに配列番号16のCDRL1配列、配列番号18のCDRL2配列、及び配列番号21のCDRL3配列を含む抗体、
(iv)配列番号1のCDRH1配列、配列番号5のCDH2配列、及び配列番号13のCDRH3配列、ならびに配列番号16のCDRL1配列、配列番号18のCDRL2配列、及び配列番号21のCDRL3配列を含む抗体、
(v)配列番号1のCDRH1配列、配列番号6のCDH2配列、及び配列番号13のCDRH3配列、ならびに配列番号16のCDRL1配列、配列番号18のCDRL2配列、及び配列番号21のCDRL3配列を含む抗体、
(vi)配列番号1のCDRH1配列、配列番号8のCDH2配列、及び配列番号13のCDRH3配列、ならびに配列番号16のCDRL1配列、配列番号18のCDRL2配列、及び配列番号21のCDRL3配列を含む抗体、
(vii)配列番号1のCDRH1配列、配列番号9のCDH2配列、及び配列番号13のCDRH3配列、ならびに配列番号16のCDRL1配列、配列番号18のCDRL2配列、及び配列番号21のCDRL3配列を含む抗体、
(viii)配列番号47または49の重鎖配列、及び配列番号30の軽鎖配列を含む抗体、
(ix)配列番号41、42、43、44、45、46、48、または49の重鎖配列またはその可変領域、及び配列番号29の軽鎖配列またはその可変領域を含む抗体、
(x)配列番号41、42、43、44、または45の重鎖配列、及び配列番号28の軽鎖配列またはその可変領域を含む抗体、
(xi)配列番号39、40、41、42、43、44、または45の重鎖配列またはその可変領域、及び配列番号27の軽鎖配列またはその可変領域を含む抗体、
(xii)配列番号38の重鎖配列またはその可変領域及び配列番号26の軽鎖配列またはその可変領域を含む抗体、
(xiii)配列番号37の重鎖配列またはその可変領域及び配列番号25の軽鎖配列またはその可変領域を含む抗体、
(xiv)配列番号48の重鎖配列またはその可変領域及び配列番号29の軽鎖配列またはその可変領域を含む抗体、ならびに
(xv)配列番号47の重鎖配列またはその可変領域及び配列番号30の軽鎖配列またはその可変領域を含む抗体、
から選択される。
(i)配列番号1のCDRH1配列、配列番号7のCDH2配列、及び配列番号13のCDRH3配列、ならびに配列番号16のCDRL1配列、配列番号18のCDRL2配列、及び配列番号22のCDRL3配列を含む抗体、
(ii)配列番号1のCDRH1配列、配列番号9のCDH2配列、及び配列番号13のCDRH3配列、ならびに配列番号16のCDRL1配列、配列番号18の配列、及び配列番号22のCDRL3配列を含む抗体、
(iii)配列番号1のCDRH1配列、配列番号4のCDH2配列、及び配列番号13のCDRH3配列、ならびに配列番号16のCDRL1配列、配列番号18のCDRL2配列、及び配列番号21のCDRL3配列を含む抗体、
(iv)配列番号1のCDRH1配列、配列番号5のCDH2配列、及び配列番号13のCDRH3配列、ならびに配列番号16のCDRL1配列、配列番号18のCDRL2配列、及び配列番号21のCDRL3配列を含む抗体、
(v)配列番号1のCDRH1配列、配列番号6のCDH2配列、及び配列番号13のCDRH3配列、ならびに配列番号16のCDRL1配列、配列番号18のCDRL2配列、及び配列番号21のCDRL3配列を含む抗体、
(vi)配列番号1のCDRH1配列、配列番号8のCDH2配列、及び配列番号13のCDRH3配列、ならびに配列番号16のCDRL1配列、配列番号18のCDRL2配列、及び配列番号21のCDRL3配列を含む抗体、
(vii)配列番号1のCDRH1配列、配列番号9のCDH2配列、及び配列番号13のCDRH3配列、ならびに配列番号16のCDRL1配列、配列番号18のCDRL2配列、及び配列番号21のCDRL3配列を含む抗体、
(viii)配列番号47または49の重鎖配列、及び配列番号30の軽鎖配列を含む抗体、
(ix)配列番号41、42、43、44、45、46、48、または49の重鎖配列,またはその可変領域、及び配列番号29の軽鎖配列またはその可変領域を含む抗体、
(x)配列番号41、42、43、44、または45の重鎖配列、またはその可変領域及び配列番号28の軽鎖配列またはその可変領域を含む抗体、
(xi)配列番号39、40、41、42、43、44、または45の重鎖配列またはその可変領域、及び配列番号27の軽鎖配列またはその可変領域を含む抗体、
(xii)配列番号38の重鎖配列またはその可変領域及び配列番号26の軽鎖配列またはその可変領域を含む抗体、
(xiii)配列番号37の重鎖配列またはその可変領域及び配列番号25の軽鎖配列またはその可変領域を含む抗体、
(xiv)配列番号48の重鎖配列またはその可変領域及び配列番号29の軽鎖配列またはその可変領域を含む抗体、ならびに
(xv)配列番号47の重鎖配列またはその可変領域及び配列番号30の軽鎖配列またはその可変領域を含む抗体、
から選択される。
本発明において、「GDF15調節物質」または「GDF15の作用を阻害する物質」とは、GDF15及び/またはGDF15の生物学的経路において、発現量、生物学的活性及び生物学的機能の低下等の結果として生じ得る、GDF15の活性及び/またはGDF15の生物学的経路の活性を、低下及び/または阻害する物質をいう。GDF15の作用を阻害する物質としては特に限定されず、例えば、GDF15のアンタゴニスト、抗GDF15抗体、GDF15特異的受容体のアンタゴニスト、抗GDF15特異的受容体抗体、GDF15特異的受容体の下流シグナルの阻害剤、GDF15の発現阻害剤、GDF15特異的受容体の発現阻害剤、GDF15がそのコグネイト結合パートナーに結合するのを阻止する可溶性GDF15模倣体または類似体、GDF15がそのコグネイト結合パートナーに結合するのを阻止する可溶性GDF15受容体模倣体または類似体、GDF15またはGDF15受容体の低分子阻害剤、干渉核酸(例えば、内在性GDF15またはコグネイト受容体の発現を干渉する干渉RNAまたはアンチセンス核酸(例えば、アンチセンスDNAまたはRNA)等が挙げられる。本発明では、これらを一種または二種以上組み合わせて用いてもよい。また、これらの物質は、公知の手法によって精製して得ることもできるし、市販品として入手することもできる。
(i)配列番号1のアミノ酸配列を含むCDRH1、配列番号7のアミノ酸配列を含むCDRH2、配列番号13のアミノ酸配列を含むCDRH3、配列番号16のアミノ酸配列を含むCDRL1、配列番号18のアミノ酸配列を含むCDRL2、及び配列番号22のアミノ酸配列を含むCDRL3、
(ii)配列番号1のアミノ酸配列を含むCDRH1、配列番号9のアミノ酸配列を含むCDRH2、配列番号13のアミノ酸配列を含むCDRH3、配列番号16のアミノ酸配列を含むCDRL1、配列番号18のアミノ酸配列を含むCDRL2、及び配列番号22のアミノ酸配列を含むCDRL3、
(iii)配列番号1のアミノ酸配列を含むCDRH1、配列番号4のアミノ酸配列を含むCDRH2、配列番号13のアミノ酸配列を含むCDRH3、配列番号16のアミノ酸配列を含むCDRL1、配列番号18のアミノ酸配列を含むCDRL2、及び配列番号21のアミノ酸配列を含むCDRL3、
(iv)配列番号1のアミノ酸配列を含むCDRH1、配列番号5のアミノ酸配列を含むCDRH2、配列番号13のアミノ酸配列を含むCDRH3、配列番号16のアミノ酸配列を含むCDRL1、配列番号18のアミノ酸配列を含むCDRL2、及び配列番号21のアミノ酸配列を含むCDRL3、
(v)配列番号1のアミノ酸配列を含むCDRH1、配列番号6のアミノ酸配列を含むCDRH2、配列番号13のアミノ酸配列を含むCDRH3、配列番号16のアミノ酸配列を含むCDRL1、配列番号18のアミノ酸配列を含むCDRL2、及び配列番号21のアミノ酸配列を含むCDRL3、
(vi)配列番号1のアミノ酸配列を含むCDRH1、配列番号8のアミノ酸配列を含むCDRH2、配列番号13のアミノ酸配列を含むCDRH3、配列番号16のアミノ酸配列を含むCDRL1、配列番号18のアミノ酸配列を含むCDRL2、及び配列番号21のアミノ酸配列を含むCDRL3、または
(vii)配列番号1のアミノ酸配列を含むCDRH1、配列番号9のアミノ酸配列を含むCDRH2、配列番号13のアミノ酸配列を含むCDRH3、配列番号16のアミノ酸配列を含むCDRL1、配列番号18のアミノ酸配列を含むCDRL2、及び配列番号21のアミノ酸配列を含むCDRL3、
を含み得る。
本明細書で開示される組成物及び方法は、対象における様々な形態の眼障害を治療するために使用することができる。本発明は、対象における眼線維化を低下するため、及び/または眼線維化障害を治療するための方法を提供する。方法は、対象における眼線維化を低下するかまたはかかる障害を治療するために、有効量のGDF15調節物質、例えば、抗GDF15抗体を、単独または別の治療剤と組み合わせて対象に投与することを含む。
GDF15調節物質を含む医薬組成物、例えば、本明細書で開示されるものは、標準的製剤技術を使用して剤型または投与単位に製剤化することができる。ただし、医薬組成物は、その意図される投与経路に適合するよう製剤化されるべきである。本発明に係る眼組織線維化抑制剤は、必要に応じて、医薬として許容される添加剤を加え、単独製剤または配合製剤として汎用されている技術を用いて製剤化することができる。
本実験例1では、レーザー誘発脈絡膜血管新生モデル(choroidal neovascularization:CNV、以下、「CNV」ともいう)におけるGDF15の局在及び発現変動について検討した。
本実験例2では、CNV病変部で高発現するGDF15の産生源について検討した。
本実験例3では、GDF15処置による網膜色素上皮細胞の細胞形態に対する影響について検討した。
本実験例4では、GDF15処置による網膜色素上皮細胞の細胞外マトリックス産生能に対する影響について検討した。
本実験例5では、GDF15を標的とした中和抗体の作用について検討した。
本実験例6では、GDF15誘発の線維化促進メカニズムについて検討した。
本実験例7では、GDF15を標的とした中和抗体の作用を検討する。
0日目に、ケタミン及びキシラジンの7:1混合麻酔液を生理食塩水で10倍希釈したもの(1mL/kg)をマウス大腿筋肉内へ投与する。その後、眼球が乾燥しないようにヒアレイン(登録商標)点眼液0.1%を点眼する。カバーガラスを右眼に宛てがいながら眼底を覗き、レーザー光凝固装置(MC500)を用いて、視神経乳頭の周囲円周上に等間隔に6箇所レーザー照射(波長:647nm、スポットサイズ:50μm、照射時間:100msec、レーザー出力:120mW)を行う。
本明細書で言及される特許文献及び科学記事の各々の開示全体は、すべての目的のために参照により組み込まれる。
本発明は、その趣旨または本質的特徴から逸脱することなく他の具体的な形態で具現化され得る。そのため、前述の実施形態は、本明細書に記載の発明に対する限定ではなく例示的なあらゆる点で考慮されるべきである。よって、本発明の範囲は、前述の説明によってではなく、添付の特許請求の範囲によって示され、特許請求の範囲の意味及び同等の範囲内に入るすべての変更は、特許請求の範囲に包含されることが意図されている。
Claims (32)
- 眼組織線維化の軽減を、それを必要とする対象において行う方法であって、前記方法は、有効量のGDF15調節物質を前記対象に投与し、それにより前記対象における眼組織線維化を軽減する、前記方法。
- 前記対象は、黄斑変性、難治性網膜硝子体疾患、糖尿病黄斑浮腫(DME)、網膜出血、網膜剥離、老眼、脈絡膜血管新生、中心窩下または中心窩近傍血管新生、角膜乱視、及び水晶体乱視から選択される障害に罹患している、請求項1に記載の方法。
- 眼線維化障害の治療を、それを必要とする対象において行う方法であって、前記方法は、有効量のGDF15調節物質を前記対象に投与し、それにより前記対象における前記障害を治療する、前記方法。
- 前記障害は、黄斑変性、難治性網膜硝子体疾患、糖尿病黄斑浮腫(DME)、網膜出血、網膜剥離、老眼、脈絡膜血管新生、中心窩下または中心窩近傍血管新生、角膜乱視、及び水晶体乱視から選択される、請求項3に記載の方法。
- 前記黄斑変性は、滲出型加齢黄斑変性である、請求項2または4に記載の方法。
- 前記難治性網膜硝子体疾患は、増殖性硝子体網膜症または糖尿病網膜症である、請求項2または4に記載の方法。
- 前記GDF15調節物質は、GDF15活性を低下させ、または阻害する、請求項1~6のいずれか1項に記載の方法。
- 前記GDF15調節物質は、抗GDF15抗体である、請求項1~7のいずれか1項に記載の方法。
- 前記抗GDF15抗体は、ヒト化抗体またはヒト抗体である、請求項8に記載の方法。
- 前記抗GDF15抗体は、
(i)配列番号1のCDRH1配列、配列番号7のCDH2配列、及び配列番号13のCDRH3配列;ならびに配列番号16のCDRL1配列、配列番号18のCDRL2配列、及び配列番号22のCDRL3配列を含む抗体、
(ii)配列番号1のCDRH1配列、配列番号9のCDH2配列、及び配列番号13のCDRH3配列;ならびに配列番号16のCDRL1配列、配列番号18の配列、及び配列番号22のCDRL3配列を含む抗体、
(iii)配列番号1のCDRH1配列、配列番号4のCDH2配列、及び配列番号13のCDRH3配列;ならびに配列番号16のCDRL1配列、配列番号18のCDRL2配列、及び配列番号21のCDRL3配列を含む抗体、
(iv)配列番号1のCDRH1配列、配列番号5のCDH2配列、及び配列番号13のCDRH3配列;ならびに配列番号16のCDRL1配列、配列番号18のCDRL2配列、及び配列番号21のCDRL3配列を含む抗体、
(v)配列番号1のCDRH1配列、配列番号6のCDH2配列、及び配列番号13のCDRH3配列;ならびに配列番号16のCDRL1配列、配列番号18のCDRL2配列、及び配列番号21のCDRL3配列を含む抗体、
(vi)配列番号1のCDRH1配列、配列番号8のCDH2配列、及び配列番号13のCDRH3配列;ならびに配列番号16のCDRL1配列、配列番号18のCDRL2配列、及び配列番号21のCDRL3配列を含む抗体、
(vii)配列番号1のCDRH1配列、配列番号9のCDH2配列、及び配列番号13のCDRH3配列;ならびに配列番号16のCDRL1配列、配列番号18のCDRL2配列、及び配列番号21のCDRL3配列を含む抗体、
(viii)配列番号47または49の重鎖配列またはその可変領域、及び配列番号30の軽鎖配列またはその可変領域を含む抗体、
(ix)配列番号41、42、43、44、45、46、48、または49の重鎖配列またはその可変領域、及び配列番号29の軽鎖配列またはその可変領域を含む抗体、
(x)配列番号41、42、43、44、または45の重鎖配列またはその可変領域、及び配列番号28の軽鎖配列またはその可変領域を含む抗体、
(xi)配列番号39、40、41、42、43、44、または45の重鎖配列またはその可変領域、及び配列番号27の軽鎖配列またはその可変領域を含む抗体、
(xii)配列番号38の重鎖配列またはその可変領域及び配列番号26の軽鎖配列またはその可変領域を含む抗体、
(xiii)配列番号37の重鎖配列またはその可変領域及び配列番号25の軽鎖配列またはその可変領域を含む抗体、
(xiv)配列番号48の重鎖配列またはその可変領域及び配列番号29の軽鎖配列、またはその可変領域を含む抗体、及び
(xv)配列番号47の重鎖配列またはその可変領域及び配列番号30の軽鎖配列、またはその可変領域を含む抗体
から選択される、請求項8または9に記載の方法。 - 前記抗GDF15抗体は、配列番号1のCDRH1配列、配列番号7のCDH2配列、及び配列番号13のCDRH3配列;ならびに配列番号16のCDRL1配列、配列番号18のCDRL2配列、及び配列番号22のCDRL3配列を含む抗体である、請求項8~10のいずれか1項に記載の方法。
- 前記抗GDF15抗体は、配列番号1のCDRH1配列、配列番号8のCDH2配列、及び配列番号13のCDRH3配列;ならびに配列番号16のCDRL1配列、配列番号18のCDRL2配列、及び配列番号21のCDRL3配列を含む抗体である、請求項8~10のいずれか1項に記載の方法。
- 前記抗GDF15抗体は、配列番号48の重鎖配列またはその可変領域及び配列番号29の軽鎖配列またはその可変領域を含む抗体である、請求項8~10のいずれか1項に記載の方法。
- 前記抗GDF15抗体は、配列番号47の重鎖配列またはその可変領域及び配列番号30の軽鎖配列、またはその可変領域を含む抗体である、請求項8~10のいずれか1項に記載の方法。
- 眼組織線維化の軽減を、それを必要とする対象において行う際に使用するためのGDF15調節物質。
- 眼線維化障害の治療を、それを必要とする対象において行う際に使用するためのGDF15調節物質。
- 眼組織線維化の軽減を、それを必要とする対象において行うための薬剤の製造において使用するためのGDF15調節物質。
- 眼線維化障害の治療を、それを必要とする対象において行うための薬剤の製造において使用するためのGDF15調節物質。
- 前記障害は、黄斑変性、難治性網膜硝子体疾患、糖尿病黄斑浮腫(DME)、網膜出血、網膜剥離、老眼、脈絡膜血管新生、中心窩下または中心窩近傍血管新生、角膜乱視、及び水晶体乱視から選択される、請求項16または18に記載のGDF15調節物質。
- 前記黄斑変性は、滲出型加齢黄斑変性である、請求項19に記載のGDF15調節物質。
- 前記難治性網膜硝子体疾患は、増殖性硝子体網膜症または糖尿病網膜症である、請求項19に記載のGDF15調節物質。
- 前記GDF15調節物質は、GDF15活性を低下させ、または阻害する、請求項15~21のいずれか1項に記載のGDF15調節物質。
- 前記GDF15調節物質は、抗GDF15抗体である、請求項15~21のいずれか1項に記載のGDF15調節物質。
- 前記抗GDF15抗体は、ヒト化抗体またはヒト抗体である、請求項23に記載のGDF15調節物質。
- 前記抗GDF15抗体は、
(i)配列番号1のCDRH1配列、配列番号7のCDH2配列、及び配列番号13のCDRH3配列;ならびに配列番号16のCDRL1配列、配列番号18のCDRL2配列、及び配列番号22のCDRL3配列を含む抗体、
(ii)配列番号1のCDRH1配列、配列番号9のCDH2配列、及び配列番号13のCDRH3配列;ならびに配列番号16のCDRL1配列、配列番号18の配列、及び配列番号22のCDRL3配列を含む抗体、
(iii)配列番号1のCDRH1配列、配列番号4のCDH2配列、及び配列番号13のCDRH3配列;ならびに配列番号16のCDRL1配列、配列番号18のCDRL2配列、及び配列番号21のCDRL3配列を含む抗体、
(iv)配列番号1のCDRH1配列、配列番号5のCDH2配列、及び配列番号13のCDRH3配列;ならびに配列番号16のCDRL1配列、配列番号18のCDRL2配列、及び配列番号21のCDRL3配列を含む抗体、
(v)配列番号1のCDRH1配列、配列番号6のCDH2配列、及び配列番号13のCDRH3配列;ならびに配列番号16のCDRL1配列、配列番号18のCDRL2配列、及び配列番号21のCDRL3配列を含む抗体、
(vi)配列番号1のCDRH1配列、配列番号8のCDH2配列、及び配列番号13のCDRH3配列;ならびに配列番号16のCDRL1配列、配列番号18のCDRL2配列、及び配列番号21のCDRL3配列を含む抗体、
(vii)配列番号1のCDRH1配列、配列番号9のCDH2配列、及び配列番号13のCDRH3配列;ならびに配列番号16のCDRL1配列、配列番号18のCDRL2配列、及び配列番号21のCDRL3配列を含む抗体、
(viii)配列番号47または49の重鎖配列またはその可変領域、及び配列番号30の軽鎖配列またはその可変領域を含む抗体、
(ix)配列番号41、42、43、44、45、46、48、または49の重鎖配列またはその可変領域、及び配列番号29の軽鎖配列またはその可変領域を含む抗体、
(x)配列番号41、42、43、44、または45の重鎖配列またはその可変領域、及び配列番号28の軽鎖配列またはその可変領域を含む抗体、
(xi)配列番号39、40、41、42、43、44、または45の重鎖配列またはその可変領域、及び配列番号27の軽鎖配列またはその可変領域を含む抗体、
(xii)配列番号38の重鎖配列またはその可変領域及び配列番号26の軽鎖配列またはその可変領域を含む抗体、
(xiii)配列番号37の重鎖配列またはその可変領域及び配列番号25の軽鎖配列をまたはその可変領域含む抗体、
(xiv)配列番号48の重鎖配列またはその可変領域及び配列番号29の軽鎖配列またはその可変領域を含む抗体、及び
(xv)配列番号47の重鎖配列またはその可変領域及び配列番号30の軽鎖配列またはその可変領域を含む抗体
から選択される、請求項23または24に記載のGDF15調節物質。 - 前記抗GDF15抗体は、配列番号1のCDRH1配列、配列番号7のCDH2配列、及び配列番号13のCDRH3配列;ならびに配列番号16のCDRL1配列、配列番号18のCDRL2配列、及び配列番号22のCDRL3配列を含む抗体である、請求項23~25のいずれか1項に記載のGDF15調節物質。
- 前記抗GDF15抗体は、配列番号1のCDRH1配列、配列番号8のCDH2配列、及び配列番号13のCDRH3配列;ならびに配列番号16のCDRL1配列、配列番号18のCDRL2配列、及び配列番号21のCDRL3配列を含む抗体である、請求項23~25のいずれか1項に記載のGDF15調節物質。
- 前記抗GDF15抗体は、配列番号48の重鎖配列またはその可変領域及び配列番号29の軽鎖配列またはその可変領域を含む抗体である、請求項23~25のいずれか1項に記載のGDF15調節物質。
- 前記抗GDF15抗体は、配列番号47の重鎖配列またはその可変領域及び配列番号30の軽鎖配列またはその可変領域を含む抗体である、請求項23~25のいずれか1項に記載のGDF15調節物質。
- GDF15(Growth Differentiation Factor 15)の作用を阻害する物質を有効成分とする、眼組織線維化抑制剤。
- 前記GDF15の作用を阻害する物質は、抗GDF15抗体、またはGDF15特異的受容体のアンタゴニストである、請求項30に記載の眼組織線維化抑制剤。
- 前記眼組織は、網膜色素上皮細胞である、請求項29または30に記載の眼組織線維化抑制剤。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020237017586A KR20230095097A (ko) | 2020-10-30 | 2021-10-29 | 눈 조직 섬유화의 저해에 사용하기 위한 gdf15 조절 물질 |
CA3199951A CA3199951A1 (en) | 2020-10-30 | 2021-10-29 | Gdf15 modulators for use in inhibiting ocular tissue fibrosis |
AU2021367458A AU2021367458A1 (en) | 2020-10-30 | 2021-10-29 | Gdf15 modulator for use in inhibition of ocular tissue fibrosis |
JP2022559458A JPWO2022092326A1 (ja) | 2020-10-30 | 2021-10-29 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020-182538 | 2020-10-30 | ||
JP2020182538 | 2020-10-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2022092326A1 true WO2022092326A1 (ja) | 2022-05-05 |
WO2022092326A8 WO2022092326A8 (ja) | 2022-10-27 |
Family
ID=81382668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/040902 WO2022092326A1 (ja) | 2020-10-30 | 2021-10-29 | 眼組織線維化の阻害に使用するためのgdf15調節物質 |
Country Status (5)
Country | Link |
---|---|
JP (1) | JPWO2022092326A1 (ja) |
KR (1) | KR20230095097A (ja) |
AU (1) | AU2021367458A1 (ja) |
CA (1) | CA3199951A1 (ja) |
WO (1) | WO2022092326A1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090012030A1 (en) * | 2007-07-02 | 2009-01-08 | Alcon Research, Ltd. | RNAi-MEDIATED INHIBITIN OF HTRA1 FOR TREATMENT OF MACULAR DEGENERATION |
WO2019245012A1 (ja) * | 2018-06-21 | 2019-12-26 | 第一三共株式会社 | 網膜色素変性症治療用ペプチド |
WO2020039321A2 (en) * | 2018-08-20 | 2020-02-27 | Pfizer Inc. | Anti-gdf15 antibodies, compositions and methods of use |
JP2020521491A (ja) * | 2017-06-01 | 2020-07-27 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Htra1発現を調節するためのアンチセンスオリゴヌクレオチド |
-
2021
- 2021-10-29 AU AU2021367458A patent/AU2021367458A1/en active Pending
- 2021-10-29 CA CA3199951A patent/CA3199951A1/en active Pending
- 2021-10-29 JP JP2022559458A patent/JPWO2022092326A1/ja active Pending
- 2021-10-29 WO PCT/JP2021/040902 patent/WO2022092326A1/ja active Application Filing
- 2021-10-29 KR KR1020237017586A patent/KR20230095097A/ko active Search and Examination
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090012030A1 (en) * | 2007-07-02 | 2009-01-08 | Alcon Research, Ltd. | RNAi-MEDIATED INHIBITIN OF HTRA1 FOR TREATMENT OF MACULAR DEGENERATION |
JP2020521491A (ja) * | 2017-06-01 | 2020-07-27 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Htra1発現を調節するためのアンチセンスオリゴヌクレオチド |
WO2019245012A1 (ja) * | 2018-06-21 | 2019-12-26 | 第一三共株式会社 | 網膜色素変性症治療用ペプチド |
WO2020039321A2 (en) * | 2018-08-20 | 2020-02-27 | Pfizer Inc. | Anti-gdf15 antibodies, compositions and methods of use |
Non-Patent Citations (2)
Title |
---|
CHLOE STANTON; ELOD KORTVELY; CAROLINE HAYWARD; MARIUS UEFFING; ALAN WRIGHT: "The serine protease HTRA1 is a potential regulator of the inflammatory cytokine GDF15", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 54, no. 15, 1 January 2013 (2013-01-01) - 9 May 2013 (2013-05-09), US , XP009536544, ISSN: 0146-0404 * |
KAZUTSUGU ISHIDA, KEI TAKAHASHI, SHINSUKE NAKAMURA, MASAMITSU SHIMAZAWA, HIDEAKI HARA: "B-07 Role of GDF15 in epithelial-mesenchymal transition of retinal pigment epithelial cells", ABSTRACTS OF THE 136TH JAPANESE PHARMACOLOGICAL SOCIETY KINKI SUBCOMMITTEE; NOVEMBER 23, 2019, 1 November 2019 (2019-11-01) - 23 November 2019 (2019-11-23), JP, pages 42, XP009536214 * |
Also Published As
Publication number | Publication date |
---|---|
WO2022092326A8 (ja) | 2022-10-27 |
AU2021367458A1 (en) | 2023-06-08 |
CA3199951A1 (en) | 2022-05-05 |
JPWO2022092326A1 (ja) | 2022-05-05 |
KR20230095097A (ko) | 2023-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11958905B2 (en) | Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody | |
RU2734678C2 (ru) | Генетическая конструкция | |
EP3197493B1 (en) | Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent | |
PT1869085E (pt) | Novo anticorpo anti-plgf | |
US20130315893A1 (en) | Humanized anti-il-20 antibody and uses thereof | |
KR20120130752A (ko) | 혈관신생-관련된 안질환의 치료를 위한 조성물 및 방법 | |
AU2021203523A1 (en) | Treatment of chronic kidney disease and other renal dysfunction using a GDF15 modulator | |
US20210260168A1 (en) | Compositions and methods of fas inhibition | |
EP3877399A1 (en) | Cell-based gene therapy for neurodegenerative diseases | |
WO2022092326A1 (ja) | 眼組織線維化の阻害に使用するためのgdf15調節物質 | |
US20230135501A1 (en) | Gene therapy | |
US20240050529A1 (en) | Modulating lymphatic vessels in neurological disease | |
WO2020022438A1 (ja) | 網膜線維化を伴う眼疾患の処置剤 | |
US20190201500A1 (en) | Compositions and methods of fas inhibition | |
JPWO2007043629A1 (ja) | エフリンb2を用いる血管新生の抑制方法 | |
CN117467025B (zh) | 一种抗vegf和补体双功能融合蛋白及其应用 | |
JP7456584B2 (ja) | 腫瘍標的化タンパク質又はその断片、それに結合する抗体及びその使用 | |
US20210024937A1 (en) | Methods of Modulating Lymphangiogenesis, E.g., to Treat Corneal Transplant Rejection, in a Subject | |
KR20230159847A (ko) | 염증성 또는 활성화된 세포를 표적으로 하고 염증성 상태 및 통증을 치료 또는 개선하기 위한 조성물 및 방법 | |
WO2022086501A1 (en) | Methods and compositions for treating ocular vascular disorders | |
JP2011529452A (ja) | 抗血管新生薬としての可溶性igf受容体 | |
NZ746729A (en) | Compositions for treatment of wet age-related macular degeneration | |
Lloris | American Society for Gene and Cell Therapy (ASGCT)-18th Annual Meeting. New Orleans, Louisiana, USA-May 13-16, 2015 | |
NZ787256A (en) | Compositions For Treatment of Wet Age-Related Macular Degeneration | |
EA042620B1 (ru) | Лечение хронического заболевания почек и другого нарушения функции почек при помощи модулятора gdf15 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21886443 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022559458 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3199951 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20237017586 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021367458 Country of ref document: AU Date of ref document: 20211029 Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21886443 Country of ref document: EP Kind code of ref document: A1 |